ESMO 2020

To strengthen the oncology portfolio, Merck collaborated with Seattle Genetics, and Gilead acquired

Novartis Beovu demonstrated non-inferiority vs. aflibercept in the PEP and superiority in SEP

MSVirtual2020: Novartis and Roche, two Swiss giants, presents robust trial results of their assets

Merck announced trial results of gefapixant in patients with refractory or unexplained chronic cough

FDA approved Trelegy Ellipta for asthma, GSK’s triple therapy is now available for asthma and COPD

Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC

Gene therapy developer AveXis renamed as Novartis Gene Therapies

European Society of Cardiology Congress 2020

FDA extended emergency use authorization of Veklury to all hospitalized patients

Bayer submitted vericiguat for market authorization in China

Bayer’s Xofigo received approval for prostate cancer in China

FDA has provided emergency use authorization for Abbott’s easy-to-use COVID-19 antigen test

European Commission approved GSK’s Blenrep for relapsed and refractory multiple myeloma

AUGUST: NICE ASSESSMENT OUTCOMES

Novartis presented robust clinical trial data of asciminib for chronic myeloid leukemia

BMS announced to acquire Forbius, targets to strengthen oncology and fibrosis portfolio

FDA issued Emergency Use Authorization of Convalescent Plasma for COVID-19 treatment

Merck’s Keytruda received one more indication and dosage form approval in Japan